Sera Prognostics Inc., a Salt Lake City-based company focused on improving maternal and neonatal health, has named Mark Capone to its board of directors. Capone is a healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees. In his most recent operating role, he served as CEO of Myriad Genetics.
Prior to serving as CEO, he held several senior leadership roles at Myriad during his 17-year tenure, including president and chief operating officer. Earlier in his career, Capone held leadership positions at Eli Lilly and other healthcare organizations.
Keep reading SLBJ
